These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8563072)

  • 21. Improvement of patient convenience in treatment with growth hormone.
    Jørgensen JT
    J Pediatr Endocrinol; 1994; 7(2):175-80. PubMed ID: 8061763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacterial contamination of growth hormone solution and injection equipment during use by growth hormone deficient children.
    Zweens MJ; Drayer NM; Dankert J
    J Hosp Infect; 1991 Jun; 18(2):123-30. PubMed ID: 1678757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen.
    Ignaut DA; Schwartz SL; Sarwat S; Murphy HL
    Diabetes Educ; 2009; 35(5):789-98. PubMed ID: 19783767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of injection dose force, accuracy and precision among three growth hormone injection devices.
    Kappelgaard AM; Hansen NÅ
    Expert Rev Med Devices; 2013 May; 10(3):321-7. PubMed ID: 23560872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Automatic needle insertion diminishes pain during growth hormone injection.
    Main KM; Jørgensen JT; Hertel NT; Jensen S; Jakobsen L
    Acta Paediatr; 1995 Mar; 84(3):331-4. PubMed ID: 7780258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Growth hormone (GH) deficiency treatment in children: comparison between uses of pen versus bottles/syringes on GH administration].
    Marchisotti FG; Carvalho LR; Berger K; Arnhold IJ; Mendonça BB
    Arq Bras Endocrinol Metabol; 2007 Oct; 51(7):1093-6. PubMed ID: 18157384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
    Kappelgaard AM; Mikkelsen S; Knudsen TK; Fuchs GS
    J Pediatr Endocrinol Metab; 2011; 24(7-8):489-96. PubMed ID: 21932587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings.
    Aronson R; Gibney MA; Oza K; Bérubé J; Kassler-Taub K; Hirsch L
    Clin Ther; 2013 Jul; 35(7):923-933.e4. PubMed ID: 23790553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
    Matfin G; Van Brunt K; Zimmermann AG; Threlkeld R; Ignaut DA
    J Diabetes Sci Technol; 2015 Apr; 9(5):1071-9. PubMed ID: 25901022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth hormone delivery devices: current features and potential for enhanced treatment adherence.
    Rohrer TR; Horikawa R; Kappelgaard AM
    Expert Opin Drug Deliv; 2017 Nov; 14(11):1253-1264. PubMed ID: 27718757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humalog(®) KwikPen™: an insulin-injecting pen designed for ease of use.
    Schwartz SL; Ignaut DA; Bodie JN
    Expert Rev Med Devices; 2010 Nov; 7(6):735-43. PubMed ID: 21050084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab.
    Kivitz A; Segurado OG
    Expert Rev Med Devices; 2007 Mar; 4(2):109-16. PubMed ID: 17359217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The redesigned follitropin alfa pen injector: results of the patient and nurse human factors usability testing.
    Schertz JC; Saunders H; Hecker C; Lang B; Arriagada P
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1111-20. PubMed ID: 21843107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes.
    LaRue S; Malloy J
    J Diabetes Sci Technol; 2015 Jul; 9(4):815-21. PubMed ID: 25759181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective comparison of clinical outcomes and satisfaction using reconstituted recombinant gonadotropins (rFSH) or cartridge rFSH with a pen device in donor oocyte cycles.
    Christianson MS; Barker MA; Schouweiler C; Lindheim SR
    Curr Med Res Opin; 2007 Apr; 23(4):865-70. PubMed ID: 17407643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new pen device for injection of recombinant human growth hormone: a convenience, functionality and usability evaluation study.
    Sauer M; Abbotts C
    Patient Prefer Adherence; 2018; 12():27-34. PubMed ID: 29343946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An open-label acceptability study of Norditropin SimpleXx--a new liquid growth hormone formulation.
    Stanhope R; Buchanan C; Butler G; Costigan C; Dunger D; Greene S; Hoey H; Hughes I; Kelnar C; Kirk J; Komulainen J; Lowry M; Warner J
    J Pediatr Endocrinol Metab; 2001 Jun; 14(6):735-40. PubMed ID: 11453523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pen device for injection of recombinant human growth hormone: a European usability engineering study.
    Cachemaille A; Warren SE; Moss S
    Expert Opin Drug Deliv; 2020 Jul; 17(7):1041-1048. PubMed ID: 32543910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic material in needles and cartridges after insulin injection with a pen in diabetic patients.
    Le Floch JP; Herbreteau C; Lange F; Perlemuter L
    Diabetes Care; 1998 Sep; 21(9):1502-4. PubMed ID: 9727898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient acceptability of a new 3.0 ml pre-filled insulin pen.
    D'Eliseo P; Blaauw J; Milicević Z; Wyatt J; Ignaut DA; Malone JK
    Curr Med Res Opin; 2000; 16(2):125-33. PubMed ID: 10893656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.